

RECEIVED
CENTRAL FAX CENTER

OCT 23 2006

AMGEN INC.

One Amgen Center Drive
Thousand Oaks, CA 91320
(805) 499-5725

Telecopier Number: (805) 499-8011 or (805) 447-1090

DATE: October 23, 2006

TO: Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
FAX # 571-273-8300

FROM: Timothy J. Gaul
Phone: (805) 447-2688


RE: U.S. Patent Appln. Ser. No. 10/645,784
Filed: August 18, 2003
Entitled: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS
Inventors: Feige, et al.
Group Art Unit: 1639
Our Ref: A-527E

Enclosed are the following:

1. 1 page Amendment Transmittal/Fee Authorization, including Request for three (3) Mo Ext. (in duplicate)
2. 13 pages Response to Office Action

There are a total of 16 pages being transmitted. This transmission may contain confidential and/or privileged information intended solely for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If all pages are not received or if you have received this facsimile in error, please notify us immediately by calling (805) 447-6855.

PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL				Attorney's Docket No: A-527E		
Serial No. 10/645,784	Filing Date August 18, 2003	Examiner Wessendorf, Teresa	Group Art Unit 1639			
In Re Application of: <i>Feige et al.</i>						
For MODIFIED PEPTIDES AS THERAPEUTIC AGENTS						
TO THE COMMISSIONER FOR PATENTS:						
<input checked="" type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):						
<input type="checkbox"/> One month of original due date (\$120.00) <input type="checkbox"/> Two months of original due date (\$450.00) <input checked="" type="checkbox"/> Three months of original due date (\$1,020.00) <input type="checkbox"/> Four months of original due date (\$1,590.00) <input type="checkbox"/> Five months of original due date (\$2,160.00)						
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested:						
<input checked="" type="checkbox"/> is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuing application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.						
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required. <input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
CLAIMS AS AMENDED						
(1)	(2) Claims remaining After amendment	(3)	(4) Highest number Previously paid for	(5) No. of Extra claims present	(6) Rate	(7) Additional Fee
Total Claims		Minus	=	0	x \$50	= \$ 0.00
Indep. Claims		Minus	=	0	x \$200	= \$ 0.00
					+	\$360
						= \$ 0.00
<input type="checkbox"/> First Appearance of a multiple dependent claim						\$ 0.00
Total Additional Fee for this Amendment						\$ 0.00
* If the entry in column 2 is less than the entry in column 4, write "0" in column 5. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.						
<input type="checkbox"/> The following other fees are incurred by the accompanying papers.						
<input type="checkbox"/> Other: _____						
<input checked="" type="checkbox"/> Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$1,020.00. A duplicate copy of this petition is attached.						
<input checked="" type="checkbox"/> If an additional extension of time is required, please consider this a request therefore.						
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees, which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.						
Please Send Future Correspondence To:						
21069						
U.S. Patent Operations/TJG						
Dept. 4300, M/S 28-2-C						
AMGEN INC.						
One Amgen Center Drive						
Thousand Oaks, California 91320-1799, USA						
 Timothy J. Gaud Attorney/Agent for Applicant(s) Registration No.: 33,111 Phone: (805) 447-2688 Date: October 23, 2006						

RECEIVED
CENTRAL FAX CENTER

OCT 23 2006

10/25/2006 AMONDAF1 00000174 010519 10645784

01 FC:1253 1020.00 DA

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

 10/23/06
 Date


 Signature

**RECEIVED
CENTRAL FAX CENTER**

OCT 23 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige *et al.*

Serial No.: 10/645,784

Group Art Unit No.: 1639

Filed: August 18, 2003

Examiner: Teresa D. Wessendorf

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

AMENDMENT AND RESPONSE TO OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A response to the Office Action dated April 21, 2006, regarding the above-identified patent application, is filed herewith.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper

Remarks/arguments begin on page 6 of this paper.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

10/23/06
date

[Signature]
Signature